Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NN-Labs Receives $2 million in SBIR Contracts

NN-Labs Receives $2 million in SBIR Contracts

Fayetteville, AR | Posted on October 17, 2006

­NN-Labs, LLC (Nanomaterials and Nanofabrication Laboratories), an Arkansas based nanotechnology firm, was recently awarded three Small Business Innovation Research (SBIR) contracts. The awards consist of two Phase II contracts, from the National Institutes of Health (NIH) and the National Science Foundation (NSF), and one Phase I contract from NIH; all three contracts total $1.8 million. Work on these new projects is already underway.

The funds will aid in NN-Labs’ ability to extend its strength in nanocrystals into end products in the biomedical field. Currently, cadmium containing semiconductor nanocrystals constitute all of the company’s standardized product lines for semiconductor nanocrystals, also known as quantum dots. While non-cadmium containing nanomaterials, such as gold nanoparticles and iron oxide (Fe3O4) magnetic Nanoparticles, are available through custom orders, the product lines are not yet complete or standardized.

The NIH Phase II, entitled Kits for Converting Nanocrystals to Standard Bio-Medical Reagents, Second Generation Nanocrystal Bio-Medical Labels follows the success of the Phase I that focused on the development of bio-medical labels based on the first generation of semiconductor nanocrystals, CdSe quantum dots. NN-Labs will develop the second generation of quantum dots, which are doped zinc containing semiconductor nanocrystals (d-dots). D-dots will ultimately remove heavy metal cadmium from the current workhorse—cadmium selenide related nanocrystals—of quantum dots. In addition, d-dots are also more durable and have better optical properties when high density emitters are needed. It is expected that these new fluorescence labels will make early diagnosis of various diseases and pathogens more practical and less expensive.

Commercial Scale Production of High Quality and Affordable Fe3O4 Nanocrystals for Nano-Biomedicine is the title of the NSF Phase II contract that will expand upon the product line developed in the Phase I contract. The biomedical applications for these Fe3O4 magnetic nanocrystals cover many aspects of the biomedical field, ranging from diagnostics, detection, therapy, separation, and pollution control, etc, which is at least a multi-billion-dollar market. Yet another variety of nanocrystal is to be developed with funding from the NIH Phase I contract, entitled High Yield and Inexpensive Production of High Quality Gold Nanocrystals as Bio-Labels. Similar to the other contracts, the end goal is to enhance already existing biomedical techniques as well as open the door to novel applications in the biomedical field. NN-Labs strives to complete this Phase I as successfully as we have for other Phase I awards, which will help us to secure the corresponding Phase II award from NIH with additional funding of $750K for two years.

NN-Labs has been business active for about four years, since July of 2002. The company has received 15 SBIR contracts (about $5m in total) that have partially funded the development of four standardized product lines, with several other product lines that are still under development and in the trial sales stage. The company maintains affiliations with the University of Arkansas and the Arkansas Science and Technology Authority (ASTA). NN-Labs is also a member of the Genesis Technology Incubator. Additional information about NN-Labs can be found on the company’s website, www.nn-labs.com, or by contacting Leah Sheridan at 479-575-2723 or lmbulla@nn-labs.com.

####

Contact:
Leah Sheridan
479-575-2723
lmbulla@nn-labs.com

Copyright © NN-Labs, LLC

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016

Harris & Harris Group Announces Formation of Co-Investment Fund for Accredited Investors March 9th, 2016

Arrowhead to Present at Upcoming March Conferences March 1st, 2016

Nanomedicine

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Nanoparticles hold promise as double-edged sword against genital herpes April 28th, 2016

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 April 28th, 2016

The Translational Research Center at the University Hospital of Erlangen in Germany uses the ZetaView from Particle Metrix to quantify extracellular vesicles such as exosomes April 28th, 2016

Materials/Metamaterials

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Exploring phosphorene, a promising new material April 29th, 2016

Hybrid nanoantennas -- next-generation platform for ultradense data recording April 28th, 2016

Atomic magnets using hydrogen and graphene April 27th, 2016

Announcements

Spintronics for future information technologies: Spin currents in topological insulators controlled May 2nd, 2016

Nanoparticles present sustainable way to grow food crops May 1st, 2016

Clay nanotube-biopolymer composite scaffolds for tissue engineering May 1st, 2016

Cooling graphene-based film close to pilot-scale production April 30th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic